Mizuho says the firm just learned that Hikma and Pfizer (PFE) settled their current tafamidis litigation. The firm believes a “major overhang” has been removed on BridgeBio (BBIO) shares. Mizuho expects the terms should be favorable for Pfizer. The settlement is likely occurring somewhere in the 2033-2035 timeframe, implying BridgeBio could potentially trade into the $90-$110 range on the near-term, the analyst tells investors in a research note. Shares of BridgeBio are up 5% to $78.58 in morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Apparent Hikma settlement ‘key positive’ for BridgeBio, says Barclays
- 3 Best Stocks to Buy This Week, According to Analysts – April 26-May 1
- BridgeBio Buy Rating Reiterated as Analyst Sees Extended Patent Runway, Delayed Tafamidis Competition and Maintains $100 Price Target
- Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
- BridgeBio initiated with an Outperform at RBC Capital